195 related articles for article (PubMed ID: 3036539)
1. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
[TBL] [Abstract][Full Text] [Related]
2. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
3. B cell activation by the nontransforming P3HR-1 substrain of the Epstein-Barr virus (EBV).
Hu CP; Aman P; Masucci MG; Klein E; Klein G
Eur J Immunol; 1986 Jul; 16(7):841-5. PubMed ID: 3013647
[TBL] [Abstract][Full Text] [Related]
4. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.
Tedder TF; Goldmacher VS; Lambert JM; Schlossman SF
J Immunol; 1986 Aug; 137(4):1387-91. PubMed ID: 3016095
[TBL] [Abstract][Full Text] [Related]
5. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
Mold C; Cooper NR; Nemerow GR
J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
[TBL] [Abstract][Full Text] [Related]
7. Activation of human thymocytes after infection by EBV.
Paterson RL; Kelleher CA; Streib JE; Amankonah TD; Xu JW; Jones JF; Gelfand EW
J Immunol; 1995 Feb; 154(3):1440-9. PubMed ID: 7822809
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
9. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus infection and replication in a human epithelial cell system.
Li QX; Young LS; Niedobitek G; Dawson CW; Birkenbach M; Wang F; Rickinson AB
Nature; 1992 Mar; 356(6367):347-50. PubMed ID: 1312681
[TBL] [Abstract][Full Text] [Related]
11. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
Cordier M; Calender A; Billaud M; Zimber U; Rousselet G; Pavlish O; Banchereau J; Tursz T; Bornkamm G; Lenoir GM
J Virol; 1990 Mar; 64(3):1002-13. PubMed ID: 2154588
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
13. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
14. CR2 ligands modulate human B cell activation.
Bohnsack JF; Cooper NR
J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
[TBL] [Abstract][Full Text] [Related]
16. In vitro transformation by Epstein-Barr virus induces a switch in growth factor and anti-IgM responsiveness in a human leukemic B cell clone.
Janssen O; Gillis S; Kabelitz D
Eur J Immunol; 1990 Jan; 20(1):7-14. PubMed ID: 2155117
[TBL] [Abstract][Full Text] [Related]
17. Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
Takimoto T; Sato H; Ogura H; Miyawaki T; Glaser R
Cancer Res; 1986 May; 46(5):2541-4. PubMed ID: 3008992
[TBL] [Abstract][Full Text] [Related]
18. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
Carel JC; Frazier B; Ley TJ; Holers VM
J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
[TBL] [Abstract][Full Text] [Related]
19. Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth.
Gordon J; Walker L; Guy G; Brown G; Rowe M; Rickinson A
Immunology; 1986 Aug; 58(4):591-5. PubMed ID: 2426189
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.
Ehlin-Henriksson B; Mowafi F; Klein G; Nilsson A
Immunology; 2006 Mar; 117(3):379-85. PubMed ID: 16476057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
